Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

msh id	COM:LYELL
symbol	LYEL
name	Lyell Immunopharma, Inc.
homepage url	https://www.lyell.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	224
crunchbase url	-
linkedin url	-
founders	-

market cap	402.8M
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.11
growth cost of revenue	0.23
growth depreciation and amortization	0.12
growth ebitda	-0.3
growth ebitda ratio	-842.7
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.43
growth gross profit	-1.29
growth gross profit ratio	-193.13

COM:LYELL

Lyell Immunopharma, Inc.

Last Close

1.03

21/11 21:00

Market Cap

402.80M

Beta: -

Volume Today

1.25M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	247.14M
cost of revenue	247.14M
depreciation and amortization	20.25M
ebitda	-213.84M
ebitda ratio	-1.64K
eps	-0.93
eps diluted	-0.93
operating expenses	247.14M
operating income	-247.01M
operating income ratio	-1.9K

accounts receivables	-
capital expenditure	-2.69M
cash at beginning of period	123.83M
cash at end of period	145.93M
inventory	-
working capital ttm	551.79M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-